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In the past decade reports from numerous clinical trials have announced 
the arrival of a new era in pharmacotherapy for retinal diseases.1 
This promises to be transformational in the fight against avoidable 
blindness where neovascular age-related macular degeneration (AMD) 
and diabetic retinopathy (DR) are recognized in a recent systematic 
review as leading causes, worldwide, of moderate and severe vision 
impairment.2 Intravitreal injection of anti-vascular endothelial growth 
factor (VEGF) therapies, such as ranibizumab,3,4 aflibercept,5 and 
bevacizumab,6,7 have transformed the prognosis of patients with 
neovascular AMD. For diabetic macular edema (DME) and retinal vein 
occlusions (RVOs), similar advances have occurred with anti-VEGF 
drugs8–11 and together with the developments in longer-acting intravitreal 
steroids,12,13 ophthalmologists now have better alternatives to offer their 
patients than ever before. 
However, the initial optimism surrounding these treatments has been 
tempered by a slow realization that real-life outcomes are less favorable 
than clinical trials and that neovascular AMD may have a much longer 
active phase than previously realized.14 Health care providers are 
struggling to meet the increasing financial demands15 of providing costly 
anti-VEGF services over a prolonged period, but perhaps more important 
is the burden on patients, carers and health care staff to maintain an 
effective therapy service that requires long-term, regular monitoring and 
treatment visits.16 This has led some commentators to question whether 
health care economies can hope to meet the ever-increasing demand of 
delivering drugs by intravitreal injections.17
It is therefore not surprising that attention has turned recently to safer, 
less-invasive and more cost-effective ways of delivering drugs to the 
posterior segment. One of the routes that is being reconsidered is 
the use of topical eye drops for retinal disease. This has traditionally been 
regarded as a poor way of delivering drugs to the posterior segment, but 
perhaps new developments discussed in this review will help challenge 
that belief.
Pharmacology of Topical Drug Delivery to the Eye
Amongst other attributes, the ideal drug for retinal disorders should be 
easy to administer, safe, have a long duration of action, and be cost-
effective. Needless to say, to date, no such drug exists as far as we 
are aware, but how close does topical delivery come to meeting these 
aspirations? Compared with intravitreal drug delivery, topical delivery has 
some obvious advantages and disadvantages and these are summarized 
in Table 1.
Maurice wrote a seminal review of this subject in 2002, in which he 
was particularly interested in the passage of drugs delivered by eye 
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drops to the posterior segment and their effect on the blood supply 
of the retina and optic nerve.18 He considered the experimental animal 
evidence of drug entry from eye drops to the posterior segment and 
concluded that only minute amounts of drug could theoretically get to 
the retina, but acknowledged that they might still have a therapeutic 
action. He described two routes by which eye drops could reach 
the retina: 
1.  Corneal—into the anterior chamber and then through the lens, the 
pupil, or the iris or its route.
2.  Conjunctival—either directly across the sclera, choroid, choriocapillaris, 
and retinal pigment epithelium (RPE); or indirectly into the retro-bulbar 
space and thence the optic nerve head.
Eye drops are in widespread use and comprise about 90 % of all ocular 
medications.19 Despite this, eye drops have considerable disadvantages as 
a means of delivering drugs into the eye, not least because the maximum 
volume that the palpebral fissure can contain under normal conditions, 
without blinking and in an upright position, is 30 μl.20 Furthermore, the 
protective mechanisms of the eye, in the form of blinking and baseline and 
reflex tearing, rapidly remove most of the eye drop-delivered drug from 
the surface of the eye, and therefore limit the time for drug penetration 
through the cornea, which for hydrophilic drugs may only be from 2 to 
5 minutes.21 To get around this, the contact time and thereby absorption 
of topical ocular medication can be prolonged by formulations such as 
gels, ointments, inserts, and contact lenses.22
The corneal epithelium is a further barrier to drug penetration into the 
eye, and is considered to be the rate-limiting factor for most drugs, 
particularly for hydrophilic compounds. It has been estimated that 
typically less than 5  % of topically applied drug permeates the cornea 
and reaches intraocular tissues.22–24 A large portion of drug applied by 
eye drops is absorbed systemically, either via the conjunctival and eyelid 
blood vessels, or via the nasopharyngeal mucosa. 
The noncorneal or conjunctival/sclera route of absorption involves 
penetration through the conjunctiva and sclera and then into intraocular 
tissues. For some drugs that have poor corneal permeability, the conjunctival/
sclera route is thought to be significant and is probably effective because 
of the larger surface area of the conjunctiva/sclera (approximately 17 times 
greater than the cornea) and because the conjunctival epithelium is much 
more permeable than the corneal epithelium and allows for the passage 
of larger solutes.23,25 The sclera is a connective tissue consisting of 68 % 
water and probably acts more like a sponge than a true barrier to drug 
penetration.25 The RPE has been found to be 10–100 times less permeable 
than the sclera for large or hydrophilic drugs.26
The individual physico-chemical properties of the drug itself are probably 
the most important rate-limiting factors for posterior segment drug 
delivery. Such factors would include: the molecular radius; the molecular 
weight; the lipophilicity; the ionic charge; the shape of the drug; and the 
protein- and melanin-binding properties.25 The formulation of eye drops 
is also crucial. Ophthalmic suspensions are composed of drug particles 
usually suspended in an aqueous phase, for example prednisolone 
acetate, which require shaking before use to ensure that all the particles 
are evenly distributed and not settled at the bottom of the bottle. This can 
cause problems with achieving uniformity of dosing27 and suspensions 
are likely to suffer flocculation—the clustering in the suspension of 
particles into larger clumps of drug. 
Nonsteroidal Anti-inflammatory Drugs 
Topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs) have a 
long history of use as an adjunct to cataract surgery where they have been 
primarily used for the treatment of postoperative pain and inflammation.28 
They have anti-inflammatory properties mediated by the inhibition of 
the cyclo-oxygenase (COX) pathway and prostaglandin synthesis. There 
are certainly three isoforms of COX—COX-1 and COX-2 being the most 
important—but in ocular disease their relative importance is not clear.29 
Following early reports of the benefits of topical indomethacin by Miyake30 
and Yannuzzi31 for treatment of postoperative cystoid macular edema 
following cataract surgery, a variety of NSAIDs have been reported as 
being effective. Subsequently, several topical NSAIDs have been reported 
as therapy for this condition including, ketorolac,32,33 diclofenac, and, more 
recently, nepafenac and bromfenac. 
Several topical NSAIDs are available commercially, including ketorolac, 
diclofenac, nepafenac, bromfenac, and flurbiprofen. Ketorelac is reported 
to be the most important inhibitor of COX-1 whilst bromfenac and amfenac 
are the most potent inhibitors of COX-2.34
One concern about NSAIDs in prolonged use is corneal toxicity and, 
in severe cases, corneal melting, which was initially reported in 1999 in 
patients using topical diclofenac.35 Subsequently, it was suspected that 
a vitamin E solubilizer in the formulation of diclofenac was the cause of 
these severe reactions.36 However, as a result of these concerns, topical 
diclofenac was withdrawn from production for a period. However, this 
adverse effect is not so much a concern with newer preparations and may 
be ameliorated when the drug is put in a nanoparticle formulation.37
Bromfenac and nepafenac are NSAIDs that have excellent corneal 
and sclera penetration and have both been shown to reach the retina 
in therapeutic doses in animals,38,39 although bromfenac would appear 
to be superior.40 Recently, there has been interest in using bromfenac, 
ketorolac, and other NSAIDs as an adjunct to anti-VEGF drugs or 
intravitreal steroids41 for macular edema from DME, RVO,42 uveitis,41 and 
also choroidal neovascularization (CNV), as there is evidence that COX 
plays an important role in promoting angiogenesis in CNV.43
Table 1: Topical and Intravitreal Drug Delivery for Retinal 
Disorders—Comparison of Advantages/Disadvantages 
Feature Topical Delivery Intravitreal Injection
Safety ++++ +
Ease of administration ++++ +
Compliance + +++
Drug delivery to retina + Unpredictable ++++
Systemic exposure ++ ++
Cost of delivery of drug + ++++
Side effects + +
Regular monitoring Quarterly Monthly/bimonthly
Application Self Trained doctor/health  
  professional
The + symbol indicates the strength of rating for each feature.
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Some recent reports are encouraging, as they have shown that topical 
NSAIDs may be used as a combination therapy with anti-VEGFs for 
neovascular AMD44 and may have a synergistic effect. One result of this 
may be that topical NSAIDs used as a combination therapy will enable 
fewer anti-VEGF injections to be given,45 which would be a major potential 
benefit for hard-pressed injection services and for patients and carers. 
However, Zeifel et al., in a retrospective study of 21 patients, found no 
benefit of adding twice-daily topical bromfenac (0.9 %) to intravitreal 
bevacizumab or ranibizumab,46 although other more recent prospective 
studies have reported benefit from twice-daily bromfenac and further 
studies are required.47
Steroids
Traditional formulations of topical steroids, such as prednisolone acetate, 
penetrate very poorly to the retina and vitreous48 and even in aphakic eyes 
have little effect on postoperative macular edema.49 They also suffer the 
disadvantage of being formulated as ophthalmic suspensions, which have 
drawbacks for dosing and drug penetration as previously noted. However, 
more modern formulations have shown promise and difluprednate, a new 
steroid formulation, has an oil-in-water type lipid emulsion, which has 
both lipid and aqueous phases within the formulation. Emulsions allow 
drugs that are poorly water soluble to be dissolved in the lipid phase and 
together with the aqueous phase and a suitable surfactant this allows 
good absorption, more reliable dose delivery, and effective sterility.50
Nakano and others have demonstrated that steroid eye drops 
(difluprednate ophthalmic emulsion) can be effective in reducing retinal 
thickness in eyes with DME, in eyes that have been vitrectomized,51 and 
in eyes prior to vitrectomy.52 In their study of 22 eyes that had undergone 
previous vitrectomy, but had refractory DME, 11 eyes (in 10 patients) were 
treated with sub-Tenon injection of triamcinolone and 11 eyes (in seven 
patients) were treated with difluprednate eye drops four times daily 
for 1 month and thereafter twice daily, and followed up for 3 months. 
Comparable improvements of retinal thickness were observed in both 
groups, confirming clinically that these eye drops achieved therapeutic 
penetration to the macula. In a follow-up investigation by the same 
researchers, patients treated with difluprednate ophthalmic emulsion 
0.05  %, had a significant improvements in vision and retinal thickness 
compared with a control group. Although this was a small study with only 
3 months follow up, the results suggest that steroid eye drops may have 
a therapeutic role for DME.
Sigurdsson and co-workers have investigated the efficiency of delivering 
dexamethasone to the retina in rabbits via eye drops, and whether this 
can be enhanced by combining it with cyclodextrin.53 Cyclodextrins are 
circular sugar compounds that have the property of forming water-
soluble inclusion complexes thus enhancing the aqueous solubility of 
lipophilic compounds.54 Sigurdsson et al. found that in rabbit eyes the 
cyclodextrin-based 0.5 % dexamethasone eye drop was able to deliver 
significant amounts of dexamethasone to the retina and vitreous by 
topical administration. This mode of topical drug delivery is promising and 
is being investigated for a number of ocular conditions.54
Retinal Neuroprotection and Topical Medication
The strategy of treating a disease by preventing neuronal death is called 
neuroprotection and was first described in detail by Levin55 in relation 
to glaucoma, where the concept has gained widespread recognition. 
By contrast, DR has most typically been considered as a microvascular 
complication of diabetes, a view that is now beginning to change as it is 
recognized that neurodegeneration is an early event in the pathogenesis 
of DR.56 The main features of neurodegeneration (apoptosis and glial 
activation) have been found in the retinas of donors with diabetes without 
any microcirculatory abnormalities detected on ophthalmic examination 
before death.57 Research is beginning to focus on potential promising 
drugs that might be used as neuroprotective agents to prevent DR.
Brimonidine is an alpha-2 adrenergic receptor agonist, which was introduced 
in the 1990s as a topical ocular hypotensive agent.58 Brimonidine has been 
shown to protect retinal ganglion cells, bipolar cells, and photoreceptors in 
numerous models of experimental nerve injury, including retinal ischemia, 
ocular hypertension, retinal phototoxicity, and partial optic nerve crush.59 It 
is currently being evaluated in the EuroCondor clinical trial to test whether 
it is effective in preventing the development or progression of retinopathy 
in diabetic persons.57,60 
Somatostatin (SST) is a natural neuroprotective and antiangiogenic factor 
synthesized by the retina, which is downregulated in the diabetic eye. 
Recent animal research has shown that SST eye drops have a potent effect 
in preventing retinal neurodegeneration occurring in the early stages of 
DR.61 Topical SST is currently also being evaluated in the EuroCondor 
Trial,60 which will be completed in 2016.
Topical Carbonic Anhydrase Inhibitors
There is considerable evidence for the benefit of using systemic carbonic 
anhydrase inhibitors (CAI) in patients with cystoid macular edema 
associated with retinal dystrophies.62 CAI are thought to work through 
their action on membrane-bound carbonic anhydrase receptors present 
in the RPE, and other cells within the neuroretina. The first report by 
Cox et al. in 1988, used oral acetazolamide in patients with chronic 
macular edema of various different causes, but included six patients with 
retinitis pigmentosa (RP) of whom four showed improvement in vision 
and two had fluorescein angiographic improvement.63 Subsequently, oral 
acetazolamide has been used in a variety of types of CME including uveitis 
and postcataract, but it has probably been most used by ophthalmologists 
in the treatment of CME associated with retinal dystrophies. However, 
systemic CAI treatment may be limited by frequent and unpleasant side 
effects such as limb paresthesia, fatigue, depression, and loss of appetite.
Grover et al. in 1997 reported using topical CAI in retinal disease. They 
used 2  % dorzolamide ophthalmic solution in five RP patients with 
CME and compared results in a double-masked, cross-over study with 
oral acetazolamide. Overall, oral acetazolamide was found to be more 
effective, although topical dorzolamide did show some improvement of 
CME by fluorescein angiography.64 Subsequently, several investigators 
have shown that topical dorzolamide is effective in reducing CME in RP 
and other retinal dystrophies, but that it may have a limited effect on 
vision improvement and a rebound phenomenon on stopping the drug 
has been recognized.65–67
Multi-targeted Kinase Inhibitors
The attraction of developing agents that could be delivered topically and 
be active against VEGF and other growth factors has led to a quest for 
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smaller molecules than the current larger anti-VEGF drugs, which have 
to be delivered by intravitreal injection. An example is TG100801, a kinase 
inhibitor described by Doukas et al.,68 which was found to be active 
against a number of different growth factors—termed a multi-targeted 
kinase inhibitor—and that looked promising in animal studies. However, a 
pilot study (NCT00509548) was terminated and drug development, to our 
knowledge, has not continued.
Another powerful multi-targeted kinase inhibitor agent is pazopanib, 
which is approved for use by the US Food and Drug Administration 
(FDA) as an oral formulation for the treatment of renal cell carcinoma 
and soft tissue sarcoma. Pazopanib 0.5 % eye drops have been used in 
a trial investigating corneal neovascularization—preliminary results are 
promising with no serious adverse events being reported.69 It is lipophilic, 
has good permeability to the retina, and, although it has been shown 
to be effective both in reducing retinal vascular leakage and leukostasis 
in an experimental animal model of diabetes70 and in blocking VEGF-
induced vascular leakage in the mouse retina, it was ineffective in the 
rabbit model.71 Subsequent pilot human clinical trials have unfortunately 
not been promising.
Regorafenib is a kinase inhibitor that targets multiple kinases, including 
VEGF receptors 1, 2, 3, and platelet-derived growth factor beta. It has been 
shown to be effective in an animal model of corneal neovascularization 
and it is currently being evaluated in a phase I trial of neovascular AMD.72 
Topical bevacizumab is a potent treatment for corneal vascularization but 
in ordinary eye drop formulation (see below) it does not penetrate through 
the cornea into the anterior chamber and vitreous humor.73
Other Agents
Squalamine lactate (Ohr Pharmaceuticals Inc.) is a small molecule with 
antiangiogenic properties against a number of growth factors.74 It has 
shown promising results in phase I and II clinical trials and is currently 
undergoing further trials in a number of retinal disorders including 
neovascular AMD, proliferative DR, DME, and RVO. A phase II, randomized, 
double-masked, placebo-controlled study in neovascular AMD (IMPACT 
study) is ongoing, but has completed enrollment. Interim results released 
in June 2014 demonstrated benefit in visual function compared with 
placebo, and further results are awaited.
Nicotinic acetylcholine (nACh) receptors are found in vascular endothelium 
and are thought to play a role in controlling vascular permeability in the retina 
and the brain, as well as stimulating CNV.75 Mecamylamine is a nonspecific 
receptor antagonist nACh that was used as an oral antihypertensive 
agent in the 1950s. It reduces blood pressure by blocking neuronal nACh-
mediated transmission at sympathetic ganglia, permitting blood vessels to 
dilate. In a multicenter phase I/II clinical trial, 1 % mecamylamine eye drops 
were given to patients with chronic DME, twice daily for 12 weeks. The 
results of this pilot trial were mixed with some patients improving, some 
unchanged, and some deteriorating. Overall, however, the drug was well 
tolerated with no drug-related safety problems.76
OC-10X (Ocucure Therapeutics) is a selective tubulin inhibitor under 
development for the treatment of neovascular AMD as a topical agent 
and may be a promising new approach to treatment. It is a quinazolinone, 
is highly lipid soluble, and has a low molecular weight of 300 Daltons and 
has good penetrance into the retina, choroid, and vitreous. A phase I trial 
(NCT 01869933) assessing the ocular and systemic safety and tolerability 
of this drug was completed in 2013.
Serine-rich protein kinase-1 (SRPK1) has been identified as a regulator of 
pro-angiogenic VEGF splicing. Recent laboratory studies in rodent models 
have shown that SRPK1 inhibitors, namely SRPIN340 and a novel furan 
molecule, are potent and selective SRPK1 inhibitors and can reduce CNV 
when given by topical administration.77
OT-551 (Othera Pharmaceuticals) is a disubstituted hydroxylamine 
compound that is converted to an active component Tempol-H, which 
has anti-oxidant properties and has been reported to protect RPE cells 
in vitro and animal experiments.78 OT-551 eyedrops (0.45 %) were used in 
Table 2: Strategies for Enhancing Ocular Availability  
of Topically Applied Drugs
Description Strategy Drug-delivery 
System
Comment
Microemulsions 
 
Penetration  
enhancer 
Lipid based 
 
Surfactants 
increase membrane 
permeability
Nanoemulsions Sustained  
release
Lipid based Positive charge allows 
binding with mucin
Liposomes 
 
Sustained release 
 
Lipid based 
 
Allows slow release  
of drug and fewer  
toxic effects
Solid lipid 
nanoparticles 
Sustained  
release/penetration 
enhancer
Lipid based 
 
Interacts with lipid  
layer of tear film 
Hydrogel Sustained release Polymeric Used as drug reservoir
Contact lens Sustained release Polymeric Used as drug reservoir
Nanoparticles 
 
Sustained release 
 
Polymeric 
 
Nanospheres or 
nanocapsules contain  
drug for delivery
Dendrimers 
 
Sustained release 
 
Polymeric 
 
Repetitively branched 
molecules in the 
nanometer scale
Iontophoresis 
 
Penetration  
enhancer 
Physical method 
 
Improves drug 
bioavailability using 
electric current
Sonophoresis 
 
Penetration  
enhancer 
Physical method 
 
Improves drug 
bioavailability using 
ultrasound
Table 3: Advantages of Liposomes as Drug Carriers
 
•	 Lipid	composition,	size,	and	electric	charge	can	be	controlled
•	 	Modification	with	surface	polymers,	carbohydrates,	and	antibodies	can	be	
achieved to facilitate targeting
•	 Liposomes	have	low	toxicity	and	antigenicity
•	 Biodegradable	and	metabolized	in vivo
•	 Membrane	permeability	may	be	controllable
•	 Liposomes	can	hold	variety	of	fat-	and	water-soluble	molecules
Source: Honda et al.88
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a phase II trial in 10 patients with bilateral GA, with one eye randomized 
to treatment and the other eye serving as a control.79 The drug was found 
to be well tolerated by participants from ocular and systemic aspects, 
but did not produce any significant benefit in terms of limiting geographic 
atrophy (GA) lesion area enlargement, although there appeared to be a 
slight benefit in best corrected visual acuity favoring the study eye. A 
fellow, larger trial, with 137 participants followed for up to a maximum of 
18 months in a randomized, parallel group, placebo-controlled trial also 
showed no benefit.80
Tandospirone (AL-8309B) is a selective serotonin 1A agonist that has been 
shown to be neuroprotective in animal models.59 It was evaluated in the 
Geographic Atrophy Treatment Evaluation (GATE) study, which was a large 
multicenter, randomized, double-blind trial to evaluate the effect of topical 
tandospirone 1.0 % and 1.75 % ophthalmic solutions in participants with 
geographic atrophy. The study failed to show any benefit in terms of mean 
annualized lesion enlargement rate from baseline and was terminated 
(Clinical Trials.gov NCT00890097).
Means of Enhancing Drug Delivery to the Retina
The two major limiting factors for using topical medication for posterior 
segment conditions are the poor drug penetration to the retina and a 
short duration of action. The strategies that have been employed to 
increase drug bioavailability can be broadly divided into those that 
enhance drug penetration and those that provide sustained-release drug 
delivery, and are summarized in Table 2, modified from the recent paper 
by Souza et al.81 and are discussed below. 
Iontophoresis is a noninvasive method of moving charged active compounds 
across membranes and it is reported that it was first used on the eye in 
1908 by Wirtz, who studied the delivery of zinc salts for the treatment of 
corneal ulcers, although it was in the 1940s that it became more widely 
used for anterior segment disease.81,82 It works by the application of a small 
electric current across the eye and has recently been used to facilitate 
ocular penetration to the posterior segment as well.83 Currently, several 
technologies are available for iontophoresis including the Eyegate II System 
(EyeGate Pharma, Waltham, MA, US), Ocuphor (Iomed Inc., Salt Lake City, UT, 
US), and Visulex (Aciont Inc., Salt Lake City, UT, US). Recently iontophoresis 
has been combined with nanoparticle delivery systems to improve the 
ocular penetration of nanoparticulate drugs.84,85
Nanotechnology (nano from the Greek for dwarf) is a term used for 
technologies that use the properties of nanoscale substances to develop 
new functions, and it is being used for many applications in the medical 
field. In the field of drug-delivery systems, nanotechnology is being used 
in three ways: to enhance absorption and penetration of drugs across 
membranes; to allow controlled release of the drug; and to target drugs 
at distinct tissues.86,87
Liposomes are one sphere of interest in nanotechnology that may prove 
successful. They are small lipid vesicles composed of a phospholipid 
bilayer, which have both aqueous and lipid phases. Therefore, water-
soluble drugs can be incorporated into their aqueous phase whereas 
lipid-soluble drugs can be enclosed into their lipid phase,88 which 
makes it possible to deliver drugs across a wide spectrum of biological 
membranes. Honda et al.,88 have also highlighted additional advantages 
that liposomes possess, and these are summarized in Table 3. They are 
currently being investigated as a means of delivering a wide variety of 
drugs to the retina, both topically and by intravitreal injection. These 
include, among others, topical avastin,89 diclofenac,90 nucleic acids and 
gene therapy,91 and numerous antibiotic and antiviral drugs.92
Conclusions
The ability to use topical medication to treat retinal and choroidal disorders 
could revolutionize the current care of many blinding disorders. However, 
the delivery of drugs to the posterior segment by noninvasive, topical 
means remains an extremely challenging goal, as shown by the small 
number of topical drugs that have so far been successfully developed. 
Nevertheless advances in novel drug-delivery systems for the posterior 
segment using topical medications may usher in a new, safer means of 
treating major blinding disorders, and bring our quest for the “perfect 
retinal drug” a step nearer. ■
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